In preclinical tumor models, Navoximod, when combined with anti-PD-L1 therapy, more effectively activates tumor-infiltrating CD8+ T cells and inhibits tumor growth in mice compared to single-agent treatments. This evidence concerns the gene CD274 and neoplasm.